JAMP MIFEPRISTONE / MISOPROSTOL DIN 02568055
Health Canada record
| Active ingredient(s) | MIFEPRISTONE 200 MG; MISOPROSTOL 200 MCG |
|---|---|
| Dosage form | Tablet |
| Route | Buccal; Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | G03XB51 MIFEPRISTONE, COMBINATIONS |
| Original market date | |
| Current status date | 06-May-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Jamp Pharma Corporation — licence 100590, currently licensed, last inspection rating C (2025-01-13).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing MIFEPRISTONE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02560569 | FEMYSO | LUPIN PHARMA CANADA LIMITED | Tablet; Kit | MIFEPRISTONE 200 MG; MISOPROSTOL 200 MCG | Marketed |
| 02444038 | MIFEGYMISO | LINEPHARMA INTERNATIONAL LIMITED | Tablet; Kit | MIFEPRISTONE 200 MG; MISOPROSTOL 200 MCG | Marketed |
| 02533553 | MIFISO | LINEPHARMA INTERNATIONAL LIMITED | Kit; Tablet | MIFEPRISTONE 200 MG; MISOPROSTOL 200 MCG | Approved |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 37487 | 2026-05-06 | Abbreviated New Drug Submission (ANDS) |
International API supply for MIFEPRISTONE
5 active FDA Drug Master Files.
Request a quote for JAMP MIFEPRISTONE / MISOPROSTOL